{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000003","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.266850+00:00","generated_at":"2026-06-20T19:50:39.916290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M","bullets":["Expects 2022 net product revenue at top of guidance range of $105M-$110M.","Year-end cash, cash equivalents, and short-term investments >$120M, above previous $110M-$120M range.","FDA approved a generic version of Keveyis (dichlorphenamide); company believes it can defend the franchise.","Does not anticipate need to raise equity to fund operations, citing commercial momentum and cash position.","Q4 and FY22 financial results to be reported on or about March 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000003","json":"https://secwatch.observer/filing/0001867096-23-000003.json","markdown":"https://secwatch.observer/filing/0001867096-23-000003.md","text":"https://secwatch.observer/filing/0001867096-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/0001867096-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/xers-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:50:39.916290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fe3178cc6e04d923aad408500f345abc5dd51fd","claim":"Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022 Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/0001867096-23-000003-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}